Article Sidebar
Published:
May 27, 2014DOI:
10.4314/tjpr.v13i4.6Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Evaluation of Genotoxicity of CSE1034 by Ames and <i>In vitro</i> Chromosomal Aberration Tests
Abstract
Purpose: To evaluate the genotoxicity of CSE1034, a novel antibiotic adjuvant entity, using bacterial reverse mutation assay (Ames test) and in vitro chromosomal aberration test.
Methods: Reverse mutation test was carried out using four strains of Salmonella typhimurium (TA 98, TA100, TA1535 and TA1537) and one strain of E. coli [WP2 (uvrA)], while chromosomal aberration test was done with cultured Chinese hamster lung (CHL) cells. Reverse mutation test was carried out in a dose range of 0.0015 to 0.16 ìg/plate in triplicate with and without S9 activation.
Results: No significant increases in the number of revertants were observed at the dose levels where antibacterial effects were not noted. CSE1034 caused no increase in the number of chromosomal aberrants at dose levels of 0.34, 0.69, 1.37, 2.75 and 5.50 mg/ml in the absence and presence of
metabolic activation.
Conclusion: Based on the above observations, it can be concluded that CSE1034 has no mutagenic activity.
Keywords: CSE1034, reverse mutation, antibiotic adjuvant entity, Chromosomal aberration, Mutagenic
